Market Cap 67.69M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,701,500
Avg Vol 2,169,052
Day's Range N/A - N/A
Shares Out 70.70M
Stochastic %K 66%
Beta -0.14
Analysts Strong Sell
Price Target $7.00

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
Creisi
Creisi Dec. 5 at 4:44 AM
$BMEA FYI: A food trial is excellent because it derisks the drug. It uses scientific measurements of blood, liver enzymes, kidney function, heart, thyroid, etc. Even the specific enzymes responsible in the cytochrome P450 (CYP450) family, found in the smooth endoplasmic reticulum of the liver will enable advanced knowledge of any potential drug to drug or food interactions. This is achieved because drug interactions and food interactions occur when the substances battle to be metabolized through the same enzymes. (i.e.One substance may inhibit what the other needs to be broken down and metabolized properly which leads to abnormal drug/blood concentrations and potential clinical drug failure.) Food trials rely on actual measured in-vivo responses, not patient responses. A food trial all but eliminates any concern over safety including side effects & drug interactions with the FDA. Clinical failure is minimized. Clinical biopharma also becomes an ideal target for Big Pharma!
1 · Reply
uwmctothemoon19191
uwmctothemoon19191 Dec. 5 at 4:08 AM
$BMEA & $MLTX nice! 😎
0 · Reply
Creisi
Creisi Dec. 5 at 3:38 AM
$BMEA True, however obtaining clinically significant p-values is far more difficult in small numbers. Therefore the mathematical likelihood of it transferring into large scale trials is highly likely. Had the p-value not reached clinical significance and effected only a couple of patients out of ten; then your narrative would be accurate. Given the factor achieved significance and that p-value significance was maintained after only 12 weeks of dosing for a full 52 weeks gives the odds of failure at or near zero.
3 · Reply
Mr_GA
Mr_GA Dec. 5 at 3:13 AM
$BMEA Had dropped to $1.25. OVERNIGHT QUOTE
0 · Reply
LouKojak
LouKojak Dec. 5 at 2:33 AM
$BMEA don't forget the food study due any day this month
0 · Reply
LouKojak
LouKojak Dec. 5 at 2:08 AM
$BMEA got any questions?
0 · Reply
Apes_Strong
Apes_Strong Dec. 5 at 1:43 AM
$BMEA Materiality therefore depends on the quantitative details tomorrow: magnitude of C‑peptide change, durability off‑treatment, consistency across doses, and how clean the safety/tolerability profile looks in this more insulin‑deficient population.
0 · Reply
Apes_Strong
Apes_Strong Dec. 5 at 1:43 AM
$BMEA they sent me this : tomorrow’s poster shows that C‑peptide gains in insulin‑deficient T2D remain statistically robust and clinically relevant out to 52 weeks (or beyond) with only 8–12 weeks of dosing, it strengthens the case that icovamenib is not just another GLP‑1/SGLT2‑type chronic therapy but a finite‑course, mechanism‑driven β‑cell intervention. That is particularly important because current agents do not regenerate β‑cell mass; durable recovery of endogenous insulin secretion in a hard‑to‑treat, insulin‑deficient phenotype is a differentiated, “category‑creating” claim if it reproducibly holds up in larger, dedicated phase II programs. The data to date are from relatively small escalation cohorts, with the 52‑week readout focusing on roughly ten severe insulin‑deficient patients in the 12‑week arms, so any β‑cell/disease‑modification narrative still rests on limited N.
0 · Reply
Mr_GA
Mr_GA Dec. 5 at 1:17 AM
$BMEA https://phl17.com/phl17-news/ozempic-is-coming-for-your-fat-cats-and-dogs/
0 · Reply
Mr_GA
Mr_GA Dec. 5 at 1:06 AM
$BMEA Just a reminder that this is happening tomorrow.
0 · Reply
Latest News on BMEA
Biomea Fusion to Participate at Upcoming Investor Conferences

Nov 24, 2025, 7:00 AM EST - 10 days ago

Biomea Fusion to Participate at Upcoming Investor Conferences


Biomea Fusion, Inc. - Special Call

Oct 7, 2025, 12:05 PM EDT - 2 months ago

Biomea Fusion, Inc. - Special Call


Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 2 months ago

Biomea Fusion Announces Proposed Public Offering of Securities


Biomea Fusion (BMEA) Q2 Loss Drops 44%

Aug 5, 2025, 10:21 PM EDT - 4 months ago

Biomea Fusion (BMEA) Q2 Loss Drops 44%


Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 6 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR


Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 9 months ago

Biomea Fusion Announces Leadership Transition


Creisi
Creisi Dec. 5 at 4:44 AM
$BMEA FYI: A food trial is excellent because it derisks the drug. It uses scientific measurements of blood, liver enzymes, kidney function, heart, thyroid, etc. Even the specific enzymes responsible in the cytochrome P450 (CYP450) family, found in the smooth endoplasmic reticulum of the liver will enable advanced knowledge of any potential drug to drug or food interactions. This is achieved because drug interactions and food interactions occur when the substances battle to be metabolized through the same enzymes. (i.e.One substance may inhibit what the other needs to be broken down and metabolized properly which leads to abnormal drug/blood concentrations and potential clinical drug failure.) Food trials rely on actual measured in-vivo responses, not patient responses. A food trial all but eliminates any concern over safety including side effects & drug interactions with the FDA. Clinical failure is minimized. Clinical biopharma also becomes an ideal target for Big Pharma!
1 · Reply
uwmctothemoon19191
uwmctothemoon19191 Dec. 5 at 4:08 AM
$BMEA & $MLTX nice! 😎
0 · Reply
Creisi
Creisi Dec. 5 at 3:38 AM
$BMEA True, however obtaining clinically significant p-values is far more difficult in small numbers. Therefore the mathematical likelihood of it transferring into large scale trials is highly likely. Had the p-value not reached clinical significance and effected only a couple of patients out of ten; then your narrative would be accurate. Given the factor achieved significance and that p-value significance was maintained after only 12 weeks of dosing for a full 52 weeks gives the odds of failure at or near zero.
3 · Reply
Mr_GA
Mr_GA Dec. 5 at 3:13 AM
$BMEA Had dropped to $1.25. OVERNIGHT QUOTE
0 · Reply
LouKojak
LouKojak Dec. 5 at 2:33 AM
$BMEA don't forget the food study due any day this month
0 · Reply
LouKojak
LouKojak Dec. 5 at 2:08 AM
$BMEA got any questions?
0 · Reply
Apes_Strong
Apes_Strong Dec. 5 at 1:43 AM
$BMEA Materiality therefore depends on the quantitative details tomorrow: magnitude of C‑peptide change, durability off‑treatment, consistency across doses, and how clean the safety/tolerability profile looks in this more insulin‑deficient population.
0 · Reply
Apes_Strong
Apes_Strong Dec. 5 at 1:43 AM
$BMEA they sent me this : tomorrow’s poster shows that C‑peptide gains in insulin‑deficient T2D remain statistically robust and clinically relevant out to 52 weeks (or beyond) with only 8–12 weeks of dosing, it strengthens the case that icovamenib is not just another GLP‑1/SGLT2‑type chronic therapy but a finite‑course, mechanism‑driven β‑cell intervention. That is particularly important because current agents do not regenerate β‑cell mass; durable recovery of endogenous insulin secretion in a hard‑to‑treat, insulin‑deficient phenotype is a differentiated, “category‑creating” claim if it reproducibly holds up in larger, dedicated phase II programs. The data to date are from relatively small escalation cohorts, with the 52‑week readout focusing on roughly ten severe insulin‑deficient patients in the 12‑week arms, so any β‑cell/disease‑modification narrative still rests on limited N.
0 · Reply
Mr_GA
Mr_GA Dec. 5 at 1:17 AM
$BMEA https://phl17.com/phl17-news/ozempic-is-coming-for-your-fat-cats-and-dogs/
0 · Reply
Mr_GA
Mr_GA Dec. 5 at 1:06 AM
$BMEA Just a reminder that this is happening tomorrow.
0 · Reply
oldmanrizzer
oldmanrizzer Dec. 5 at 12:54 AM
$BMEA New here, doing some DD..what caused this to huge drop since March of 2023? Seems like for a buck and change might be a decent pick up. Thanks.
0 · Reply
Mr_GA
Mr_GA Dec. 5 at 12:48 AM
0 · Reply
Mr_GA
Mr_GA Dec. 5 at 12:45 AM
$BMEA https://x.com/HHS_Jim/status/1996669284614132176
0 · Reply
Apes_Strong
Apes_Strong Dec. 5 at 12:39 AM
$BMEA whispers are of durable glycemic and c peptide improvement to be presented If true, this is the start of an explosive rally This could go to $5 quickly
0 · Reply
brokeass90
brokeass90 Dec. 5 at 12:27 AM
$BMEA let’s get a $1.30 AH close price
0 · Reply
Kid_Shelleen
Kid_Shelleen Dec. 5 at 12:04 AM
1 · Reply
Alaskagainsfarmer
Alaskagainsfarmer Dec. 4 at 11:50 PM
$BMEA Somebody with $2000 bucks needs to just send it. $MLTX
0 · Reply
Apes_Strong
Apes_Strong Dec. 4 at 11:23 PM
$BMEA it’s had 10,000 shares bid at 1.23 for an hour now and no one hitting it Very very good sign
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Dec. 4 at 10:56 PM
$BMEA Let's not get too much excited for $1 . X Lots of people bought above 10, 20, 30, 40 ... This stock deserves to come back avoe $20
1 · Reply
Danzzzzzzzz
Danzzzzzzzz Dec. 4 at 10:46 PM
$BMEA yep , at least 9 M shares shorted, not ecen talking about dark pool short
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Dec. 4 at 10:43 PM
$BMEA Agreed 💯 this is a 20ish bagger
0 · Reply
Bikenchef73
Bikenchef73 Dec. 4 at 10:19 PM
$BMEA Lots of calls at $2.50. Every expiration.
0 · Reply